trial · primary record
VRT106
Glioblastoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 42 |
| Primary completion | 2029-06-30 |
| Primary endpoint | Evaluate the safety and tolerability of escalating doses of VRT106 in Patients with recurrent/progressive glioblastoma |
| Registry ID | NCT07093814 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:35.138Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07093814
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Vrt106 · compound